Domainex’s discovery platform technologies enable rapid progression of drug discovery projects, from drug target through to Candidate Drug; even for challenging drug targets!
Domainex saves time over conventional approaches, by means of its Combinatorial Domain Hunting technology for the expression of protein for structural studies and assay design, LeadBuilder virtual and fragment-based approaches to hit identification, and its integrated approach to medicinal and computational chemistry.
In a Nature Reviews Drug Discovery article (Pammolli et al., 2011), it was reported that the average drug discovery timelines within big pharma companies are 4½ years from target to Candidate Drug. However, Domainex is able to significantly reduce this time by up to 30% (9-12 months from target to lead, 2 years for lead optimization) through use of its proprietary technologies, and its innovative and creative approach to discovery. So how does Domainex achieve this large time saving? Please follow the links to find out more:
- Combinatorial Domain Hunting - screen 100,000 protein domain variants in only 3 months, to identify constructs for use in structural studies and assay development
- LeadBuilder - virtual and fragment-based approaches to hit identification. Highly efficient and with >93% success rate, due to Domainex's focus on identifying developable hits!